Online Supplemental Material. Detailed methodology for pharmacokinetic analysis of GEM and JP1201 in tumor-bearing animals are shown. Fig. S1 shows histology of tumors from mice treated in the late intervention scheme and demonstrates that mice treated with JP1201 in combination with GEM or TRAIL have reduced tumor burden and more residual normal pancreas compared with animals treated with control and single agent therapy. Fig. S2 shows controls for TNFα immunohistochemistry, demonstrating the anti-TNFα antibody has limited to no reactivity in mouse (Pan02) tumors. Table S1 displays pharmacokinetic data for GEM and JP1201 in mice bearing MIA PaCa-2 tumors. Table S2 displays TNFα protein levels in conditioned media of cells treated with JP1201 or subjected to XIAP knockdown.